NXTS

Nexentis is not an operating business you can value on fundamentals — it's a ~$22M shell-like holding company whose latest fiscal year reports no revenue at all, layered on a four-year revenue slide ($438K→$394K→$263K→$210K) that was already collapsing before it hit zero. The market is paying 104.7x sales for a company that loses money on essentially every dollar it touches: operating margin of -2014%, net margin of -1907%, and a cumulative accumulated deficit of -$38.6M. There is no profitability trend to reward and no revenue base to grow from. Diluted EPS of -$8.61 alongside a 71.3% collapse in share count signals a reverse split and serial dilution — the classic funding pattern of a going-concern micro-cap.

The MD&A confirms the enterprise is a grab-bag of unrelated, unproven bets rather than a coherent company. MitoCareX is a pre-clinical drug-discovery shop targeting 'one undisclosed SLC25A protein' for NSCLC — no clinical asset, no approval, and R&D was actually *cut* 51.5% to just $179K, which is not the spend profile of a company seriously advancing a pipeline. Bolted onto that is Solterra, a European solar-project JV in Italy/Poland/Germany, plus a churn of transactions: NTWO OFF sold, Save Foods dumped to 'Voice Assist' for illiquid stock and contingent cash payable only 'from future Voice Assist equity and/or debt financing' — i.e., consideration that may never materialize. The $20.4M asset base (+273%) and $16.0M equity are inflated by these paper/equity items, not by cash generation.